Actavis Recalls Albuterol Sulfate Inhalation Solution Due to Impurities
Actavis Inc is recalling specific lots of Albuterol Sulfate Inhalation Solution because the product failed impurity specifications for a known degradant.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The source text identifies this as an FDA Class III recall, which the rubric defines as typically scoring 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Actavis Inc is voluntarily recalling 164,844 units of Albuterol Sulfate Inhalation Solution, USP, 0.021% (0.63 mg / 3 mL), 3mL Vials. The product is manufactured for Watson Laboratories Inc. and by Cipla Ltd. The recall covers lots GA51265, GA51454, GA51553, GA51583, GA51598, GA51724, GA51725, and GA51749, with expiration dates ranging from January 2017 to March 2017.
The recall was initiated because the product is out of specification for a known degradant. This is a Class III recall, which indicates that the use of or exposure to the violative product is not likely to cause adverse health consequences.
The affected product was distributed nationwide in the US. Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed above. If the product is found, it should be returned to the pharmacy or distributor for credit or disposal, as directed by the recalling firm.
The recalled product
- Product
- Albuterol Sulfate Inhalation Solution, USP, 0.021% (0.63 mg / 3 mL), 3mL Vials, Rx only, Mfd. for Watson Laboratories Inc., Corona, CA 92880 USA, Mfd. by Cipla Ltd. Verna, Goa India, NDC 0591-3467-53
- Manufacturer
- Actavis Inc
- Category
- Drug — Inhalation Solution
- Hazard
- Affected units
- 164,844
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lot #: GA51265
- Ex[p. Jan-2017
- GA51454
- GA51553
- GA51583
- Exp. Feb-2017
- GA51598
- GA51724
- GA51725
- GA51749
- Exp. Mar-2017
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Actavis Inc
See all →- ModerateActavis Recalls Levofloxacin Ophthalmic Solution Due to Impurity Failure
FDA (Drugs) · 2017-03-15
- ModerateActavis Recalls Glipizide Extended-Release Tablets Due to Dissolution Failure
FDA (Drugs) · 2017-02-22
- LowActavis Recalls Acetasol HC Otic Solution Due to Impurity Failure
FDA (Drugs) · 2016-08-31
- LowActavis Recalls Hydrocortisone and Acetic Acid Otic Solution Due to Impurities
FDA (Drugs) · 2016-08-31
- ModerateActavis Recalls Glipizide 2.5 mg Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2016-08-24
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08